ExLibris header image
SFX Logo
Title: Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
Source:

Proceedings of the National Academy of Sciences of the United States of America [0027-8424] Guedj, J yr:2013


Collapse list of basic services Basic
Full text
Full text available via PubMed Central
GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Chayama, H. "Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study." Journal of viral hepatitis 23.11 (2016): 850-856. Link to Full Text for this item Link to SFX for this item
2. Aghemo, A. "Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C." Gut 64.6 (2015): 860-2. Link to SFX for this item
3. Cada, J. "Sofosbuvir." Hospital pharmacy 49.5 (2014): 466-78. Link to Full Text for this item Link to SFX for this item
4. Martin, Danyelle N. "Identification of transferrin receptor 1 as a hepatitis C virus entry factor." Proceedings of the National Academy of Sciences of the United States of America 110.26 (2013): 10777-10782. Link to Full Text for this item Link to SFX for this item
5. Rotman, Y. "Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C." Gut 63.1 (2013): 161-169. Link to SFX for this item
6. Reactions weekly 1540.1 (2015): 276-276. Link to SFX for this item
7. Lawitz, E. "Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection." The New England journal of medicine 368.20 (2013): 1878-1887. Link to SFX for this item
8. Wang, H. "Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis." Journal of gastroenterology and hepatology 32.1 (2017): 45-52. Link to Full Text for this item Link to SFX for this item
9. Cuenca Lopez, F. "Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C." Expert opinion on drug metabolism & toxicology. 13.1: 105-112. Link to SFX for this item
10. Hessel, Marleen H. M. F. "Sofosbuvir and daclatasvir." British journal of clinical pharmacology 82.3 (2016): 878-879. Link to Full Text for this item Link to SFX for this item
11. Feld, J. "Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection." The New England Journal of Medicine 373.27 (2015): 2599-607. Link to SFX for this item
12. Houlihan, David J. "Hepatitis A virus vaccination in persons with hepatitis C virus infection: Consequences of quality measure implementation." Hepatology 56.2 (2012): 501-506. Link to Full Text for this item Link to SFX for this item
13. RoqueCuéllar, Berta C. "Expression of CD81, SR-BI and LDLR in lymphocytes and monocytes from patients with classic and occult hepatitis C virus infection." Journal of medical virology 84.11 (2012): 1727-1736. Link to Full Text for this item Link to SFX for this item
14. Herbst, D Alan R. "NS5A inhibitor, daclatasvir , for the treatment of chronic hepatitis C virus infection." Expert opinion on investigational drugs 22.10 (2013): 1337-1346. Link to SFX for this item
15. Laurito, Marcela P. "Association between insulin resistance and sustained virologic response in hepatitis C treatment, genotypes 1 versus 2 and 3: systematic literature review and meta-analysis." The Brazilian journal of infectious diseases 17.5 (2013): 555-563. Link to Full Text for this item Link to SFX for this item
16. Dorner, M. "Completion of the entire hepatitis C virus life cycle in genetically humanized mice." Nature 501.7466 (2013): 237-241. Link to Full Text for this item Link to SFX for this item
17. Ross Thriepland, D. "The C-terminus of NS5A domain II is a key determinant of hepatitis C virus genome replication, but is not required for virion assembly and release." Journal of general virology (2013): 1009-1018. Link to SFX for this item
18. Chatterjee, A. "Hepatitis C viral kinetics: the past, present, and future." Clinics in liver disease (2013): 13-26. Link to SFX for this item
19. Feld, J. "Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response." Hepatology 46.5 (2007): 1548-1563. Link to Full Text for this item Link to SFX for this item
20. Crotty, S. "The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen." Nature medicine 6.12 (2000): 1375-1379. Link to Full Text for this item Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.